The Ultimate Systemic Support

Modulate. Recover. Prosper.

pHysioProtease® is a unique, proprietary blend of powerful, non-animal derived proteolytic enzymes that has a long history of use in effectively helping to modulate the immune system, manage inflammation, and maintain optimal systemic health.*

Get a Quote Why pHysioProtease® How it Works
  • Up to 52× Systemic Activity for Balanced, Whole-Body Support*
  • Helps Promote Recovery, Immune Balance, and Healthy Circulation*
  • Blood-Optimized pH (7.4) for Reliable Systemic Performance*
Scroll

Breaking the Inflammation Cycle

It is now generally accepted in the healthcare community that an imbalance in the body’s inflammatory response, particularly in the activity of cytokines, can greatly exacerbate existing health problems throughout the body, prolonging healing time which may lead to reoccurrence or chronicity.[1,2] A strong immune defense against harmful agents is vital to maintaining the normal structure and function of all body systems. Inflammation is an integral part of a healthy immune system, occurring when tissue has been damaged by invading microorganisms, traumatic injury, altered metabolism, oxidative stress, environmental irritants or any other physical or chemical insult to the body. The inflammatory process begins when tissue damage stimulates the release of chemical mediators including histamine, prostaglandins, leukotrienes, bradykinin and various cytokines which bring about a number of vascular and cellular changes. These chemical mediators cause blood vessels to dilate increasing blood flow to the area. Local blood vessels also become more permeable, allowing fluid and proteins including fibrin to leak into the tissues to isolate the foreign or harmful substance from other parts of the body. Cytokines attract phagocytes to the area to engulf and destroy the offending agent as well as any dead or damaged cellular material in the first step towards tissue regeneration or repair and the end of the inflammatory process.[3] If the body incorrectly identifies the cause of tissue damage or a harmful agent cannot effectively eliminate a harmful agent or there is interference in the healing process, pro-inflammatory chemical mediators will dominate and inflammation will persist.[4] Progressive tissue damage caused by even low-grade chronic inflammation can result in further functional impairment.[5] Unless this imbalance is addressed, conventional or alternative treatment methods will have difficulty resolving the initial health concern.

Cytokine Noise
What’s Happening: Excess TNF-α/IL-1β and other mediators keep the alarm on.
Why it Matters: Escalates symptoms, heightens sensitivity, fuels a flare cycle.
Resolution
What’s Happening: Poor switch from pro-inflammatory to pro-resolving pathways; debris clearance lags.
Why it Matters: Slower repair, lingering swelling/pain, reduced tissue quality over time.
Chronicity
What’s Happening: Persistent mediators and impaired remodeling lock in dysfunction.
Why it Matters: Higher recurrence risk, shortened “good” intervals, cumulative wear on systems.

How it Works


  1. Absorption & A2M Activation

    Taken between meals, the pHysioProtease® proteases resist gastric acidity, pass the stomach intact, and are absorbed from the small intestine into the bloodstream [11–14]. Once in circulation, they promptly bind α2-macroglobulin (A2M) to avoid triggering immune recognition; this binding induces a conformational change that increases A2M’s activity and mobilizes the complex toward sites of inflammation, rapidly modulating the inflammatory cascade [15–19]. This blood-phase mechanism—and its emphasis on activity under physiological conditions—is protected by U.S. Patent 6,413,512 [20].*

  2. Cardiovascular Maintenance

    Supplemental proteases in pHysioProtease® support normal fibrinolytic balance, red blood cell flexibility, and vessel wall integrity—factors that improve blood rheology and microcirculatory flow [46–49]. Better flow helps deliver oxygen, nutrients, and fibroblasts to damaged tissues more efficiently, supporting the body’s natural repair processes and recovery timeline [46–49].*

  3. Inflammation Management

    Protease-activated A2M binds pro-inflammatory cytokines (TNF-α, IL-1β) for rapid hepatic clearance while also interacting with anti-inflammatory mediators (e.g., TGF-β) that promote tissue repair [21–23]. These pathways help regulate other mediators (kinins, prostaglandins) linked to pain and edema, and influence leukocyte trafficking—tempering neutrophil influx while supporting macrophage and natural killer cell activity for more orderly resolution of inflammation [7, 24–28, 29–33].*

  4. Immune Support

    A2M-activated pathways enhance phagocytic activity (e.g., macrophages) to clear cellular debris and a range of harmful agents (microorganisms, allergens, chemicals, rogue cells) [25]. They also aid the complement system in degrading circulating and tissue-deposited immune complexes, and help clear heat- or oxidation-damaged proteins—limiting accumulation of abnormal proteins with amyloid potential [34–41]. Collectively, this “cleanup” across blood, lymph, and interstitial fluids underpins a more effective immune response and quality of life [42–45].*

The pHysioProtease® Difference

By choosing to use proteases that work best in the blood and tissue fluid, despite the additional cost, pHysioProtease® remains the most effective systemic protease blend available for modulating the inflammatory response and supporting immune and cardiovascular functions.* pHysioProtease® consists of highly purified proteolytic enzymes concentrated from non-genetically modified microorganisms, primarily Aspergillus oryzae and Aspergillus niger, with a long history of safe use. There are many types of protease derived from these microbial sources, each with its own set of parameters for optimal activity such as temperature, pH, substrate specificity, cleavage pattern, etc. The protease most commonly found in both digestive and systemic enzyme supplements is one that works best in the physiological conditions of the digestive tract as it is intended to break down dietary protein into smaller peptides and amino acids. The industry standard for measuring the activity of this protease uses FCC or Food Chemical Codex methodology based on gastrointestinal parameters. However, the physiological conditions of blood and tissue fluid are significantly different than those of the digestive tract so the standard HUT measurement does not reflect the true activity of a protease in these body fluids. Most notably, the standard FCC assay is run at a pH of 4 whereas the pH of the blood is 7.4.[50] Aware of this disparity, an innovative study was conducted by Enzymes, Inc. to measure proteolytic activity of different commercially-available systemic protease supplements adjusting the FCC testing methodology to reflect blood rather than gastrointestinal parameters. The results revealed pHysioProtease® provides up to 52 times more activity than other proteases used for systemic purposes.*

*mHUT or modified HUT is the designation given for the proteolytic activity expected in the blood and tissue fluid. This unit is based on modifying the temperature, pH, substrate and buffering mechanism of the standard FCC HUT assay to simulate the conditions found in the blood. Products A, B, and C may have high standard FCC HUT values but this merely indicates they are optimally active in the digestive tract not in the blood and tissue fluids.

Why pHysioProtease®

pHysioProtease® is a proprietary blend of non-animal proteolytic enzymes formulated for systemic use. Taken between meals, these proteases withstand gastric conditions, are absorbed intact, and operate at blood/tissue pH (7.4). In circulation they complex with α2-macroglobulin to modulate inflammatory signaling and support immune and cardiovascular function. Testing under blood-like conditions shows up to 52× higher activity versus common digestive-phase protease blends.*

  • Systemic Delivery, Optimized: Designed to resist stomach acid and be absorbed intact, then binds α2-macroglobulin in the bloodstream helping escort activity to where it’s needed and rapidly modulate the inflammatory cascade.*
  • Targeted Modulation & Recovery: Supports balanced cytokine signaling (e.g., TNF-α, IL-1β), healthy fibrinolytic activity, and effective “cleanup” by macrophages—promoting circulation, tissue repair, and whole-body resilience.*
  • Clean & Proven: Highly purified, Non-GMO microbial enzymes with a long safety record; patented mechanism and demonstrated systemic performance; pairs seamlessly with herbs, vitamins, and minerals in comprehensive protocols.*

References


  1. Kaplin MD LJ. Systemic Inflammatory Response Syndrome. emedicine.medscape.com/article/168943.
  2. Alexandraki K. et al. Inflammation process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci. 2006; 1084:89-117.
  3. Guyton AC, Hall JE. Resistance of the body to infection: I. Leukocytes, granulocytes, the monocyte-macrophage system, and inflammation. In: Textbook of Medical Physiology. Philadelphia, Pa; W.B. Saunders Company; 1996:439-442.
  4. Anft M. Understanding Inflammation. Johns Hopkins Health Review. Spring/Summer 2016. Vol 3 Issue 1.
  5. Taddei S. et al. Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto’s thyroiditis. J Clin Endocrinol Metab. 2006; 91(12):5076-82.
  6. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3.
  7. Muhammad ZA, Ahmad T. Therapeutic uses of pineapple-extracted bromelain in surgical care - A review. J Pak Med Assoc. 2017 Jan;67(1):121-125.
  8. Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee: a double-blind prospective randomized study. Clin Rheumatol. 2004;23(5):410-415.
  9. WittenBorg A et al. Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination preparation. Arzneimittelforschung. 2000; 50(8):728-38.
  10. Kleine MW, Stauder GM, Beese EW. The intestinal absorption of orally administered hydrolytic enzymes and their effects in the treatment of acute herpes zoster as compared with those of oral acyclovir therapy. Phytomedicine. 1995;2(1):7-15.
  11. Varayil MD JE, MD; Bauer MD BA, Hurt MD, PhD RT. Over-the-Counter Enzyme Supplements: What a Clinician Needs to Know. Mayo Clin Proc. September 2014; 89(9):1307-1312.
  12. Kolac C., Streichhan P., Lehr CM. Oral bioavailability of proteolytic enzymes. European Journal of Pharmaceutics and Biopharmaceutics. 1996, vol. 42, no4, pp. 222-232.
  13. Ambrus JL, et al.: Absorption of exogenous and endogenous proteolytic enzymes. Clin Pharmacol Therap 1967;8:362-8.
  14. Castell, J.V.; Friedrich, G.; Kuhn, C.S.; Poppe, G.E. “Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake”. Am J Physiol 1997; 273: G139-G146.
  15. Nouza K, Wald M. Systemic enzyme therapy: problems of resorption of enzyme macromolecules. Cas Lek Cesk 1995; 134 (19):615-9.
  16. Borth W Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992 Dec;6(15):3345-53.
  17. Garzone, PD. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules. Principles of Clinical Pharmacology 2nd ed.: 479-500.
  18. Nouza K. Outlooks of systemic enzymes therapy in rheumatoid arthritis and other immunopathological diseases. Acta Univ Carol [Med] (Praha). 1994;40(1-4):101-4.
  19. Larsson, L.J.; Frisch, E.P.; Torneke, K.; Lindblom, T. & Bjork, I. “Properties of the complex between alpha 2-macroglobulin and brinase, a proteinase from Aspergillus oryzae with thrombolytic effect”. Thromb Res 1988; 49: 55-68.
  20. Houston DB, Greaves LS, Andrews LD, Collier AW. Composition and Method for Treating Disease by Increasing Activated Alpha-2-Macroglobulin in the Blood and Extravascular Tissue. US patent 6,413,512. 1999.
  21. LaMarre J et al. Cytokine binding and clearance properties of proteinase-activated alpha- 2-macroglobulins. Lab Invest. 1991;65(1):3-14.
  22. Rehman AA, Ahsan H, Khan FH. Alpha-2-Macroglobulin: a physiological guardian. J Cell Physiol.2013 Aug;228(8):1665-75.
  23. Eming, SA, Krieg T, Davidson JM. Inflammation in Wound Repair: Molecular and Cellular Mechanisms. Journal of Investigative Dermatology. March 2007. 127(3):514-525.
  24. van Gool J , van Vugt H, de Bont E. Alpha 2-macroglobulin and fibrinogen modulate inflammatory edema in man. Inflammation. 1990 Jun;14(3):275-83.
  25. Rathnavelu V, al. Potential role of bromelain in clinical and therapeutic applications. Biomed Rep. 2016 Sep; 5(3): 283–288.
  26. Brown SA, Coimbra M, Coberly DM, Chao JJ, Rohrich RJ. Oral Nutritional Supplementation Accelerates Skin Wound Healing: A Randomized, Placebo-Controlled, Double-Arm, Crossover Study. Plastic & Reconstructive Surgery. July 2004. 114(1):237-244.
  27. Kerkhoffs Gm et al. A double blind, randomised, parallel group study on the efficacy and safety of treating acute lateral ankle sprain with oral hydrolytic Br J Sports Med. 2004 Aug; 38(4) :431-5.
  28. Klein G, Kullich W. Reducing pain by oral enzyme therapy in rheumatic diseases. Wien Med Wochenschr. 1999;149:57780.
  29. Forrester JV,  Wilkinson PC, Lackie Effect of modified alpha 2 macroglobulin on leucocyte locomotion and chemotaxis. Immunology. 1983 Oct; 50(2): 251–259.
  30. Fitzhugh DJ1, Shan S, Dewhirst MW, Hale LP. "Bromelain treatment decreases neutrophil migration to sites of inflammation." Clin Immunol. 2008 Jul;128(1):66-74.
  31. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol. 2002;104:183–190. 
  32. Misra UK, Sharma T, Pizzo SV. Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of alpha 2-macroglobulin: activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages. J Immunol.2005 Aug 15;175(4):2525-33.
  33. Stauder G. Pharmacological effects of oral enzyme combinations. Cas Lek Cesk. 1995 Oct 4;134(19):620-4.
  34. Steffen C, Menzel J. Enzyme breakdown of immune complexes. Z Rheumatol.1983 Sep-Oct;42(5):249-55.
  35. Nakazawa M. et al. Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. J Exp Med. 1986;164(6):1973-87.
  36. Gesualdo L. et al. Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria and mesangial proliferation in murine experimental IgA nephropathy. J Clin Invest. 1990;80:715-22.
  37. Steffen C et al.: Enzyme therapy in comparison with immune complex determinations in chronic polyarteritis. Rheumatologie 1985;44:51-6.
  38. Stauder G et al. The use of hydrolytic enzymes as adjuvant therapy in AIDS/ARC/LAS patients. Biomed Pharmacother. 1988;42(1):31-4.
  39. Wyatt AR et. al. Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms. FEBS Lett. 2013 Mar 1; 587(5): 398–403.
  40. French K, Yerbury JJ, Wilson MR. Protease activation of alpha2-macroglobulin modulates a chaperonelike action with broad specificity. Biochemistry. 2008 Jan 29;47(4):1176-85.
  41. Lauer D, Reichenbach A, Birkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1--42: a mechanism to enhance amyloid beta catabolism. Exp Neurol.2001 Feb;167(2):385-92.
  42. Beuth J. "Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction?" Integr Cancer Ther. 2008 Dec;7(4):311-6.
  43. Popiela T et al. Influence of a complementary treatment with oral enzymes on patients with colorectal cancers-an epidemiological retrolective cohort study. Cancer Chemother Pharmacol. 2001;47:S55-63.
  44. Leipner J, Saller R: Systemic enzyme therapy in oncology: effect and mode of action. Drugs. 2000;59:769-80.
  45. Arazi A1, Neumann AU. "Modeling immune complex-mediated autoimmune inflammation." J Theor Biol. 2010 Dec 7;267(3):426-36.
  46. Nouza K. Systemic enzyme therapy in diseases of the vascular system. Bratisl Lek Listy. 1995 Oct;96(10):566-9.
  47. Pavan R, Jain S, Shraddha, Kumar A. Properties and Therapeutic Application of Bromelain: A Review. Biotechnology Research International. 2012;2012:976203.
  48. Ley CM et al. A review of the use of bromelain in cardiovascular diseases. J of Chinese Integrative Medicine. July 2011. 9(7):702-709.
  49. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application: an update. J Ethnopharmacol. 1988;22(2):191-203.
  50. Food Chemical Codex, 12th edition.